Cingulate Inc. is a biopharmaceutical company with a mission to advance the field of therapeutics through its innovative Precision Timed Release™ (PTR) drug delivery platform technology. Founded in 2012, the company aims to address the challenges faced by patients with conditions that require burdensome daily dosing regimens and often result in suboptimal treatment outcomes. With a primary focus on treating Attention Deficit/Hyperactivity Disorder (ADHD), Cingulate Inc. envisions the potential application of its PTR technology in other therapeutic areas, including anxiety disorders.
The company's innovative drug delivery technology holds vast promise for the future of pharmaceutical products. The last recorded investment amount of $1.86M in post-IPO equity investment on 28 June 2024 underscores the growing confidence in Cingulate Inc.'s capabilities in shaping the next generation of therapeutics.
Operating within the Biotechnology and Health Care industries, Cingulate Inc. is headquartered in the United States. The company's pioneering approach to drug delivery technology places it at the forefront of medical innovation, positioning it as a compelling prospect for potential investors seeking to make an impact in advancing next-generation pharmaceutical products.
Business keywords:
biopharmaceutical, drug delivery technology, Precision Timed Release, therapeutics, ADHD, anxiety disorders, pharmaceutical products, Catalent Pharma Solutions, OptiDose technology, intellectual property, patents, stimulants, clinical use, patient efficacy, commercialization
Kansas City, United States
